Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Bausch Health Stock , BHC

7.60 0.00 0.00%
Official Close 3/17/2023 NYSE
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

Is Bausch Health stock a Buy, Sell or Hold? Bausch Health stock has received a consensus rating of buy. The average rating score is and is based on 7 buy ratings, 4 hold ratings, and 1 sell ratings.
What was the 52-week low for Bausch Health stock? The low in the last 52 weeks of Bausch Health stock was 4.00. According to the current price, Bausch Health is 190.00% away from the 52-week low.
What was the 52-week high for Bausch Health stock? The high in the last 52 weeks of Bausch Health stock was 24.26. According to the current price, Bausch Health is 31.33% away from the 52-week high.
What are analysts forecasts for Bausch Health stock? The 12 analysts offering price forecasts for Bausch Health have a median target of 17.96, with a high estimate of 55.00 and a low estimate of 4.50. The median estimate represents a 42.32 difference from the last price of 7.60.

Bausch Health Stock Snapshot

7.59
Bid
98,400.00
Bid Size
7.60
Ask
52,600.00
Ask Size
3/17/2023
Date
4:15 PM
Time
938,109.00
Volume
7.79
Prev. Close
7.68
Open
2.76 B
Market Cap
362.04 M
Number of Shares
7.53
Day Low
7.72
Day High
7.60
4.00
52 Week Low
24.26
52 Week High
7.60
0.00
Dividend
1.84
P/E Ratio
98.39
Free Float in %
3.48
EPS 2023
6.14
Book Value per Share
3.69
Cash Flow per Share

Bausch Health Historical Prices

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Bausch Health Analyst Data

Total Analysts: 12
Buy Ratings: 7 Neutral Ratings: 4 Sell Ratings: 1
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 4.50 Median: 17.96 Highest: 55.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Bausch Health Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
09/09/22 Piper Sandler
Maintained Hold $6
09/01/22 RBC Capital Markets
Maintained Hold $8
08/10/22 BMO Capital Markets
Maintained Buy $8
08/10/22 RBC Capital Markets
Maintained Hold $4.5
07/29/22 RBC Capital Markets
Downgraded to Hold $5
07/29/22 J.P. Morgan
Downgraded to Hold
07/26/22 RBC Capital Markets
Maintained Buy $12
06/13/22 J.P. Morgan
Maintained Buy $12
05/13/22 RBC Capital Markets
Maintained Buy $17
05/09/22 RBC Capital Markets
Maintained Buy $21
11/03/21 RBC Capital Markets
Maintained Buy $40
03/24/21 Bank of America Merrill Lynch
Downgraded to Sell $27
03/16/21 H.C. Wainwright & Co.
Maintained Buy $55

Bausch Health Estimates* in USD

  2023 2024 2025 2026 2027
Revenue 8,339 8,506 8,774 9,171 9,280
Dividend 0.00 0.00 - - -
Dividend Yield (in %) - - - - -
EPS 3.48 3.84 4.40 5.23 6.53
P/E Ratio 2.18 1.97 1.72 1.45 1.16
EBIT 2,829 2,979 3,156 3,423 3,486
EBITDA 3,071 3,236 3,451 3,725 3,831
Net Profit 1,272 1,409 1,614 1,935 2,444
Net Profit Adjusted 1,272 1,409 1,614 1,935 2,444
Pre-Tax Profit 1,526 1,711 1,976 2,303 2,809
Net Profit (Adjusted) 294 2,072 1,466 - -
EPS (Non-GAAP) ex. SOE 4.39 5.11 - - -
EPS (GAAP) 0.24 1.18 2.28 3.43 -
Gross Income 5,540 5,625 5,776 5,693 5,098
Cash Flow from Investing -249 -240 -240 -220 -220
Cash Flow from Operations 1,728 1,950 2,061 2,360 2,795
Cash Flow from Financing -483 -1,300 -2,712 -737 -7,428
Cash Flow per Share 3.69 4.53 - - -
Free Cash Flow 1,314 1,399 - - -
Free Cash Flow per Share 4.07 4.31 - - -
Book Value per Share 6.14 - - - -
Net Debt 20,979 15,822 - - -
Research & Development Exp. 482 473 480 445 364
Capital Expenditure 246 235 235 220 220
Selling, General & Admin. Exp. 2,233 2,138 2,160 2,060 1,765
Shareholder’s Equity 1,149 3,115 4,883 6,241 8,790
Total Assets 26,824 28,529 27,712 30,082 25,340
  Previous Quarter
ending 12/31/22 		Current Quarter
ending 03/31/23 		Next Quarter
ending 06/30/23 		Current Year
ending 12/31/23 		Next Year
ending 12/31/24
Earnings Estimates
No. of Analysts 6 4 4 6 5
Average Estimate 0.947 USD 0.733 USD 0.813 USD 3.480 USD 3.842 USD
Year Ago 1.272 USD 0.724 USD 0.554 USD 3.357 USD 3.480 USD
Publish Date 2/23/2023 5/9/2023 8/8/2023 - -
Revenue Estimates
No. of Analysts 6 4 4 6 5
Average Estimate 2,136 USD 1,961 USD 2,039 USD 8,339 USD 8,506 USD
Year Ago 2,196 USD 1,918 USD 1,967 USD 8,124 USD 8,339 USD
Publish Date 2/23/2023 5/9/2023 8/8/2023 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Bausch Health Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Carson Seana 03/05/2023 495.00 443,235.00 9.17 Sell No
Carson Seana 03/05/2023 495.00 443,235.00 9.17 Sell No
Carson Seana 03/02/2023 780.00 443,730.00 9.34 Sell No
Carson Seana 03/02/2023 887.00 444,510.00 9.16 Sell No
Carson Seana 03/02/2023 1,637.00 445,397.00 9.16 Sell No
Carson Seana 03/02/2023 511.00 447,034.00 9.16 Sell No
Carson Seana 03/02/2023 765.00 447,545.00 9.16 Sell No
APPIO THOMAS 03/02/2023 2,357.00 981,121.00 9.16 Sell No
APPIO THOMAS 03/02/2023 4,348.00 983,478.00 9.16 Sell No
APPIO THOMAS 03/02/2023 1,577.00 987,826.00 9.16 Sell No
APPIO THOMAS 03/02/2023 1,893.00 989,403.00 9.16 Sell No
Carson Seana 03/02/2023 780.00 443,730.00 9.34 Sell No
Carson Seana 03/01/2023 5,994.00 353,191.00 9.25 Sell No
Vadaketh Tom George 03/01/2023 4,001.00 466,203.00 9.25 Sell No
APPIO THOMAS 03/01/2023 17,432.00 468,141.00 9.25 Sell No
Carson Seana 03/01/2023 95,119.00 448,310.00 n/a Buy No
Vadaketh Tom George 03/01/2023 142,678.00 608,881.00 n/a Buy No
Barresi John S 03/01/2023 25,266.00 77,037.00 n/a Buy No
APPIO THOMAS 03/01/2023 523,155.00 991,296.00 n/a Buy No
Carson Seana 02/27/2023 292.00 359,185.00 9.32 Sell No
APPIO THOMAS 02/26/2023 2,069.00 485,573.00 9.57 Sell No
APPIO THOMAS 02/26/2023 4,258.00 487,642.00 9.57 Sell No
Carson Seana 02/26/2023 768.00 359,477.00 9.57 Sell No
Carson Seana 02/26/2023 1,474.00 360,245.00 9.57 Sell No
Vadaketh Tom George 01/02/2023 6,310.00 470,204.00 6.28 Sell No

Bausch Health Dividend Calendar

Date Name Dividend *yield Currency
2022 Bausch Health - - USD
2021 Bausch Health - - USD
2020 Bausch Health - - USD
2019 Bausch Health - - USD
2018 Bausch Health - - USD
2017 Bausch Health - - USD
2016 Bausch Health - - USD
2015 Bausch Health - - USD
2014 Bausch Health - - USD
2013 Bausch Health - - USD
2012 Bausch Health - - USD
2011 Bausch Health - - USD
2010 Bausch Health 1.28 4.52 USD
2009 Bausch Health 0.65 4.62 USD
*Yield of the Respective Date

Bausch Health Calendar

Event Estimate Info Date
Earnings Report 0.733 USD Q1 2023 Earnings Release 05/09/2023
Annual General Meeting - Annual General Meeting 05/16/2023
Earnings Report 0.813 USD Q2 2023 Earnings Release 08/08/2023
Earnings Report - Q3 2023 Earnings Release 11/07/2023
Earnings Report - Q4 2023 Earnings Release 02/21/2024

Bausch Health Past Events

Event Actual EPS Info Date
Earnings Report 1.047 USD Q4 2022 Earnings Release 02/23/2023
Press Conference - - 05/10/2022

Bausch Health Profile

Bausch Health Cos. , Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U. S. of GI products. Sales of the Xifaxan product line.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
9
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Bausch Health Shareholder

Owner in %
Freefloat 98.39
Carl Celian Icahn 9.59
Paulson & Co., Inc. 7.31
GoldenTree Asset Management LP 5.88
Natixis SA 4.37
Franklin Advisers, Inc. 4.36
Glenview Capital Management LLC 4.24
Franklin Income Fund 4.15
ValueAct Capital Management LP 3.99
ValueAct Holdings LP 3.96
National Bank of Canada (Subfiler) 3.62
Nomura Holdings, Inc. 3.27
Hudson Bay Capital Management LP 3.18
Laurion Capital Management LP 2.88
Goldman Sachs & Co. LLC 2.75
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.